- Home
- DOUG vs CCCC Comparison
DOUG vs CCCC Comparison
Compare DOUG & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- CCCC
- Stock Information
- Founded
- DOUG 1911
- CCCC 2015
- Country
- DOUG United States
- CCCC United States
- Employees
- DOUG N/A
- CCCC N/A
- Industry
- DOUG Building operators
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- CCCC Health Care
- Exchange
- DOUG Nasdaq
- CCCC Nasdaq
- Market Cap
- DOUG 161.5M
- CCCC 175.1M
- IPO Year
- DOUG N/A
- CCCC 2020
- Fundamental
- Price
- DOUG $2.93
- CCCC $3.38
- Analyst Decision
- DOUG
- CCCC Strong Buy
- Analyst Count
- DOUG 0
- CCCC 4
- Target Price
- DOUG N/A
- CCCC $8.50
- AVG Volume (30 Days)
- DOUG 469.9K
- CCCC 1.3M
- Earning Date
- DOUG 11-05-2025
- CCCC 10-30-2025
- Dividend Yield
- DOUG N/A
- CCCC N/A
- EPS Growth
- DOUG N/A
- CCCC N/A
- EPS
- DOUG N/A
- CCCC N/A
- Revenue
- DOUG $1,034,406,000.00
- CCCC $34,240,000.00
- Revenue This Year
- DOUG $17.61
- CCCC N/A
- Revenue Next Year
- DOUG N/A
- CCCC N/A
- P/E Ratio
- DOUG N/A
- CCCC N/A
- Revenue Growth
- DOUG 8.69
- CCCC 16.55
- 52 Week Low
- DOUG $1.35
- CCCC $1.09
- 52 Week High
- DOUG $3.20
- CCCC $7.14
- Technical
- Relative Strength Index (RSI)
- DOUG 61.73
- CCCC 69.68
- Support Level
- DOUG $2.58
- CCCC $2.58
- Resistance Level
- DOUG $2.95
- CCCC $3.65
- Average True Range (ATR)
- DOUG 0.14
- CCCC 0.24
- MACD
- DOUG 0.02
- CCCC 0.07
- Stochastic Oscillator
- DOUG 71.67
- CCCC 79.55
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.